NCT04413279View on ClinicalTrials.gov

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Dry Eye Syndromes
Interventions
PROCEDURE

LipiFlow Thermal Pulsation

To manage patients with dry eye disease secondary to MGD

DRUG

Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation

to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation

Trial Locations (1)

46040

Eye Surgeons of Indiana, Indianapolis

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.
All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Eye Surgeons of Indiana

NETWORK

NCT04413279 - Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease | Biotech Hunter | Biotech Hunter